Supplementary Financial Results (IFRS) for Fiscal 2025 (Fiscal Year Ending March 2026) | Sumitomo Pharma Co.,Ltd. (4506) timely disclosure

Worth reading

44Recurring

0–100. This measures how worthwhile something is to read, not how good or bad the company is.

Direction

Improvement

Direction inferred from the company’s description.

Scale

785

Year-on-year change in operating profit (¥ hundred million)

Wording

Avoiding a definitive answer

How definitive the wording is.

Contents of this document

Supplementary materials to the earnings reportFY2025 (fiscal year ending March 2026)7 items taken from the company’s own explanation

Financial Results Figures (The key points of this material are explained below)

Net Sales4,533 Hundred millions of yen+13.7%

Operating profit1,073 Hundred millions of yen+272.6%

Ordinary income¥1,003 100 million +469.8%profit before tax

Net income¥1,069 100 million +352.2%profit for the year attributable to owners of the parent

Operating profit margin23.7%

Selling, general and administrative expenses1,593 Hundred millions of yen

Results for the three months of the current quarter

Revenue

1,055 Hundred millions of yen

Operating profit

-24 Hundred millions of yen

Quarterly profit attributable to owners of the parent

-8 Hundred millions of yen

Full-year earnings forecast

Revenue

5,400 Hundred millions of yen

Core operating profit

910 Hundred millions of yen

Operating profit

900 Hundred millions of yen

Profit for the period attributable to owners of the parent

770 Hundred millions of yen

Basic earnings per share

¥172.89

ROE

20.3%

ROIC

15.1%

What the company explained in this material

Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.

Revenue—Japan-75 Hundred millions of yen
Revenue—North America861 Hundred millions of yen
Revenue—Asia-242 Hundred millions of yen
Partial transfer of the Asia business490 Hundred millions of yen
Selling, general and administrative expenses-84 Hundred millions of yen
Impairment losses in Japan in the previous fiscal year-55 Hundred millions of yen
Business structure improvement costs in Japan in the previous fiscal year-59 Hundred millions of yen
Business structure improvement costs in North America in the previous fiscal year-29 Hundred millions of yen
Impairment losses in North America in the current fiscal year-21 Hundred millions of yen
Change in the fair value of contingent consideration32 Hundred millions of yen

Assumptions Underlying the Business OutlookThe assumptions used by the company in preparing its forecast.

Assumed average JPY/USD exchange rate155 JPY/USD
Assumed JPY/CNY exchange rate

New initiatives

Obtaining conditional and time-limited approval in Japan for Amschepri / Laguneprocel / CT1-DAP001/DSP-1083
Initiation of Phase 1 for DSP-0551
Updates to the development pipeline

Key KPIsA metric the company considers important as a management benchmark.

Overseas Revenue Mix81.6 %
Year on year against the same period last yearUp from 76.9%
ROE46.3 %
Year on year against the same period last yearUp from 14.5%
ROIC22.8 %
Year on year against the same period last yearUp from 9.4%
MR headcount—Japan510 People
Year on year against the same period last yearUp from 450 people
MR headcount—United States440 People
Year on year against the same period last yearUp from 430 people

Segment results

Japan

Revenue

924 Hundred millions of yen

Cost of sales

501 Hundred millions of yen

Gross profit

422 Hundred millions of yen

Selling, general and administrative expenses

299 Hundred millions of yen

Core segment profit

124 Hundred millions of yen

Revenue growth-7.5%

North America

Revenue

3,379 Hundred millions of yen

Cost of sales

1,374 Hundred millions of yen

Gross profit

2,005 Hundred millions of yen

Selling, general and administrative expenses

1,247 Hundred millions of yen

Core segment profit

757 Hundred millions of yen

Revenue growth34.2%

Asia

Revenue

230 Hundred millions of yen

Cost of sales

88 Hundred millions of yen

Gross profit

142 Hundred millions of yen

Selling, general and administrative expenses

47 Hundred millions of yen

Core segment profit

95 Hundred millions of yen

Revenue growth-51.2%

Number of employees

31 March 2026

Consolidated3,123

Individual1,747

Capital expenditures

66 Hundred millions of yen

Contents of this document
Item	Details
Document type	Supplementary materials to the earnings report
Fiscal Period Covered	FY2025 (fiscal year ending March 2026)
Net Sales	4,533 Hundred millions of yen (YoY +13.7%)
Operating profit	1,073 Hundred millions of yen (YoY +272.6%)
Ordinary income	¥1,003 100 million (profit before tax) (YoY +469.8%)
Net income	¥1,069 100 million (profit for the year attributable to owners of the parent) (YoY +352.2%)
Operating profit margin	23.7%
Selling, general and administrative expenses	1,593 Hundred millions of yen
Results for the three months of the current quarter	Revenue 1,055 Hundred millions of yen / Operating profit -24 Hundred millions of yen / Quarterly profit attributable to owners of the parent -8 Hundred millions of yen
Full-year earnings forecast	Revenue 5,400 Hundred millions of yen / Core operating profit 910 Hundred millions of yen / Operating profit 900 Hundred millions of yen / Profit for the period attributable to owners of the parent 770 Hundred millions of yen / Basic earnings per share ¥172.89 / ROE 20.3% / ROIC 15.1%
Segment results	Japan Revenue 924 Hundred millions of yen / Cost of sales 501 Hundred millions of yen / Gross profit 422 Hundred millions of yen / Selling, general and administrative expenses 299 Hundred millions of yen / Core segment profit 124 Hundred millions of yen / Revenue growth -7.5% / North America Revenue 3,379 Hundred millions of yen / Cost of sales 1,374 Hundred millions of yen / Gross profit 2,005 Hundred millions of yen / Selling, general and administrative expenses 1,247 Hundred millions of yen / Core segment profit 757 Hundred millions of yen / Revenue growth 34.2% / Asia Revenue 230 Hundred millions of yen / Cost of sales 88 Hundred millions of yen / Gross profit 142 Hundred millions of yen / Selling, general and administrative expenses 47 Hundred millions of yen / Core segment profit 95 Hundred millions of yen / Revenue growth -51.2%
Breakdown of Factors Affecting the Change	Factors Revenue—Japan / Amount -75 Hundred millions of yen, Factors Revenue—North America / Amount 861 Hundred millions of yen, Factors Revenue—Asia / Amount -242 Hundred millions of yen, Factors Partial transfer of the Asia business / Amount 490 Hundred millions of yen, Factors Selling, general and administrative expenses / Amount -84 Hundred millions of yen, Factors Impairment losses in Japan in the previous fiscal year / Amount -55 Hundred millions of yen, Factors Business structure improvement costs in Japan in the previous fiscal year / Amount -59 Hundred millions of yen, Factors Business structure improvement costs in North America in the previous fiscal year / Amount -29 Hundred millions of yen, Factors Impairment losses in North America in the current fiscal year / Amount -21 Hundred millions of yen, Factors Change in the fair value of contingent consideration / Amount 32 Hundred millions of yen
Key KPIs	Indicator name Overseas Revenue Mix / Value 81.6 % / Year on year against the same period last year Up from 76.9%, Indicator name ROE / Value 46.3 % / Year on year against the same period last year Up from 14.5%, Indicator name ROIC / Value 22.8 % / Year on year against the same period last year Up from 9.4%, Indicator name MR headcount—Japan / Value 510 People / Year on year against the same period last year Up from 450 people, Indicator name MR headcount—United States / Value 440 People / Year on year against the same period last year Up from 430 people
Number of employees	31 March 2026 Consolidated 3,123 / Individual 1,747 / Change during the period Not disclosed
Assumptions Underlying the Business Outlook	Item Assumed average JPY/USD exchange rate / Value 155 JPY/USD, Item Assumed JPY/CNY exchange rate / Value Not disclosed
Capital expenditures	66 Hundred millions of yen
New initiatives	Obtaining conditional and time-limited approval in Japan for Amschepri / Laguneprocel / CT1-DAP001/DSP-1083, Initiation of Phase 1 for DSP-0551, Updates to the development pipeline

Items this document does not state (14)

Gross Profit MarginProgress against full-year forecastSelf-assessment against the planUnit price and quantity metricsNumber of stores and locationsRisk amount incorporated into the outlookMedium-term management plan targetsFinancial targetsAnnual DividendPayout ratioAcquisition of treasury sharesOrders received and order backlogMarket Size / ShareKey points of the Q&A

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

An ¥8.61 billion increase in revenue in North America, a ¥49.0 billion gain from the partial transfer of the Asia business, an ¥8.4 billion decrease in selling, general and administrative expenses, and the absence of the impairment losses and business structure improvement costs recorded in the previous fiscal year, among other factors.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.

Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.

Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.